Inflammatory Endotype–associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis

Zhang Wang, Nicholas Locantore, Koirobi Haldar, Mohammadali Yavari Ramsheh, Augusta Beech, Wei Ma, James R. Brown, Ruth Tal‐Singer, Michael R. Barer, Mona Bafadhel, Gavin C. Donaldson, Jadwiga A. Wedzicha, Dave Singh, Tom Wilkinson, Bruce E. Miller, Christopher E. BrightlingAmerican 2020 · DOI

TL;DR

This study reveals that the airway microbiome in COPD is not monolithic but can be stratified into distinct subtypes within neutrophilic patients, influencing their inflammatory profiles and temporal stability. These microbiome subtypes can dynamically shift, even switching between neutrophilic and eosinophilic inflammation, suggesting a potential for microbiome-based diagnostics and personalized therapies.

What Problem Does This Paper Address?

Chronic Obstructive Pulmonary Disease (COPD) is a complex and heterogeneous disease characterized by diverse clinical presentations and underlying inflammatory mechanisms. While it's known that the airway microbiome plays a role in COPD, its specific association with different inflammatory endotypes (neutrophilic vs. eosinophilic) and how this relationship changes over time, particularly during stable periods versus exacerbations, remains unclear. Understanding these dynamics is crucial for developing targeted, microbiome-informed diagnostic and therapeutic strategies for COPD patients. This paper aims to dissect the intricate interplay between airway microbiome composition and the inflammatory endotypes of COPD, focusing on longitudinal changes.

Methods

The researchers employed an integrative analysis of a large dataset of sputum samples collected longitudinally from patients with COPD. Key methods included:

  • 16S rRNA Gene Sequencing: This standard technique was used to characterize the bacterial communities present in the sputum samples. Different sequencing platforms (Illumina MiSeq and 454 Genome Sequencer) were used across cohorts, with efforts made to harmonize the data.
  • Unsupervised Clustering: Algorithms like hierarchical clustering and partition around the medoids were used to identify distinct community types within the airway microbiome, allowing for the discovery of novel subgroups without pre-defined classifications.
  • Inflammatory Mediator Assays: Sputum and serum samples were analyzed for a panel of inflammatory cytokines and chemokines using the Meso Scale Discovery platform to link microbiome profiles to specific inflammatory pathways.
  • Time-Series Analysis (Changepoint Detection): This advanced statistical approach was used to identify significant shifts in the microbiome composition over time within individual patients, correlating these changes with their inflammatory status.
  • Network Analysis (Co-occurrence and Correlation): SparCC was used to build microbiome co-occurrence networks, and hierarchical association testing (HAllA) was employed to assess correlations between microbiome genera and inflammatory mediators, revealing host-microbiome interactions.

Datasets

The study utilized data from three large, longitudinal UK cohorts:

  • COPDMAP (Chronic Obstructive Pulmonary Disease Medical Research Council/Association of the British Pharmaceutical Industry): Used as a discovery dataset.
  • AERIS (Acute Exacerbation and Respiratory Infections in COPD): Also used as a discovery dataset.
  • BEAT-COPD (Biomarkers to Target Antibiotic and Systemic COPD): Used as a validation dataset.

In total, 1,706 sputum samples were collected from 510 patients with COPD. The study did not introduce new benchmark datasets but rather integrated existing, well-characterized cohorts.

Key Insights and Ideas

  • Neutrophilic COPD is Heterogeneous: The most striking finding is that neutrophilic COPD is not a single entity but can be divided into at least two distinct airway microbiome subtypes. This challenges the traditional view of neutrophilic inflammation as a uniform state.
  • Microbiome as a Stratification Tool: The identified microbiome subtypes are associated with different inflammatory mediator profiles and temporal stability, suggesting that the microbiome can serve as a powerful tool to stratify patients for more targeted therapies.
  • Dynamic Interplay Between Microbiome and Inflammation: The study highlights that the airway microbiome is not static but can dynamically shift, particularly in certain neutrophilic subgroups. This dynamism is linked to switches between neutrophilic and eosinophilic inflammatory states, suggesting a fluid relationship.
  • The "Balanced" Microbiome as a Transition State: A "balanced" microbiome subtype within neutrophilic COPD appears to be a key transitional state, being more susceptible to shifts during exacerbations and capable of switching to both Haemophilus-predominant neutrophilic and eosinophilic states.
  • Microbiome as a Real-time Inflammatory Indicator: The temporal variability of the airway microbiome can track a patient's inflammatory status, hinting at the potential for microbiome-based point-of-care diagnostics.

Key Results

  • Two Main Neutrophilic Subtypes: The airway microbiome in neutrophilic COPD was classified into two primary community types: Haemophilus-predominant and a "balanced" microbiome.
  • Haemophilus-Predominant Subgroup: Associated with elevated sputum IL-1β and TNFα, and showed relative temporal stability.
  • Balanced Microbiome Subgroup: Associated with elevated sputum and serum IL-17A, and was temporally dynamic. This subgroup was most susceptible to microbiome shifts during exacerbations and could switch to both Haemophilus-predominant and eosinophilic states.
  • Interchangeability of Endotypes: Neutrophilic and eosinophilic COPD states were found to be interchangeable in some patients, with the balanced neutrophilic subtype acting as a bridge.
  • Specific Genera Linked to Eosinophilia: Genera like Campylobacter and Granulicatella showed temporal trajectories indicative of switches from neutrophilic to eosinophilic inflammation. Additionally, specific nondominant genera were enriched in eosinophilic COPD, independent of Haemophilus predominance.
  • Distinct Host-Microbiome Interactions: Network analysis revealed unique interaction patterns between the microbiome and inflammatory mediators for each of the identified subgroups.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sputum vs. Lower Airway Ecology: The use of sputum samples, which can include oral microbes, may not perfectly recapitulate the lower airway ecology. Further evaluation of oral microbe contributions is needed.
  • Longitudinal Sampling Sparsity: While longitudinal, the sampling frequency was limited, potentially hindering a finer-scale examination of temporal variability. More intensive follow-up could provide deeper insights.
  • Limited Host Omics Data: The study focused on the microbiome and inflammatory mediators. The absence of other host omics data (e.g., transcriptomics) limits a more comprehensive understanding of gene signatures and immune processes.
  • Observational Nature and Confounders: The study is observational, meaning associations do not imply causation. Confounders such as ICS treatment and antibiotic use were present, necessitating further interventional studies.
  • Underrepresentation of Female Participants: The generalizability of findings may be limited due to the underrepresentation of female participants.

Future work should focus on interventional studies to confirm causality, explore the role of IL-17A and microbiome modulation strategies (like probiotics), and investigate the potential for microbiome-based diagnostics for real-time inflammatory status monitoring.

Summary updated

Abstract

<b>Rationale:</b> Understanding the role of the airway microbiome in chronic obstructive pulmonary disease (COPD) inflammatory endotypes may help to develop microbiome-based diagnostic and therapeutic approaches. <b>Objectives:</b> To understand the association of the airway microbiome with neutrophilic and eosinophilic COPD at stability and during exacerbations. <b>Methods:</b> An integrative analysis was performed on 1,706 sputum samples collected longitudinally from 510 patients with COPD recruited at four UK sites of the BEAT-COPD (Biomarkers to Target Antibiotic and Systemic COPD), COPDMAP (Chronic Obstructive Pulmonary Disease Medical Research Council/Association of the British Pharmaceutical Industry), and AERIS (Acute Exacerbation and Respiratory Infections in COPD) cohorts. The microbiome was analyzed using COPDMAP and AERIS as a discovery data set and BEAT-COPD as a validation data set. <b>Measurements and Main Results:</b> The airway microbiome in neutrophilic COPD was heterogeneous, with two primary community types differentiated by the predominance of <i>Haemophilus</i>. The <i>Haemophilus</i>-predominant subgroup had elevated sputum IL-1β and TNFα (tumor necrosis factor α) and was relatively stable over time. The other neutrophilic subgroup with a balanced microbiome profile had elevated sputum and serum IL-17A and was temporally dynamic. Patients in this state at stability were susceptible to the greatest microbiome shifts during exacerbations. This subgroup can temporally switch to both neutrophilic <i>Haemophilus-predominant</i> and eosinophilic states that were otherwise mutually exclusive. Time-series analysis on the microbiome showed that the temporal trajectories of <i>Campylobacter</i> and <i>Granulicatella</i> were indicative of intrapatient switches from neutrophilic to eosinophilic inflammation, in track with patient sputum eosinophilia over time. Network analysis revealed distinct host-microbiome interaction patterns among neutrophilic <i>Haemophilus</i>-predominant, neutrophilic balanced microbiome, and eosinophilic subgroups. <b>Conclusions:</b> The airway microbiome can stratify neutrophilic COPD into subgroups that justify different therapies. Neutrophilic and eosinophilic COPD are interchangeable in some patients. Monitoring temporal variability of the airway microbiome may track patient inflammatory status over time.
BibTeX
@inproceedings{wang2020inflammatory,
  author = {Zhang Wang and Nicholas Locantore and Koirobi Haldar and Mohammadali Yavari Ramsheh and Augusta Beech and Wei Ma and James R. Brown and Ruth Tal‐Singer and Michael R. Barer and Mona Bafadhel and Gavin C. Donaldson and Jadwiga A. Wedzicha and Dave Singh and Tom Wilkinson and Bruce E. Miller and Christopher E. Brightling},
  title = {{Inflammatory Endotype–associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis}},
  booktitle = {American},
  year = {2020},
  doi = {10.1164/rccm.202009-3448oc},
}
Figure